SIGHT GenSight Biologics S.A.

0.0835USD0.0761 EUR · EPA0.00%Mkt Cap: 20.47M USDP/E: —

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company deve…

Institutional holders2 on file

Key Statistics

Company
Market Cap20.47M USD
Enterprise Value31.82M USD
Revenue (TTM)-275.30K USD
Gross Profit-275.30K USD
Net Income (TTM)-13.20M USD
Revenue/Share-0.0011 USD
Last Price0.0835 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013183985
Valuation
P/E (Trailing)—
P/E (Forward)-0.09
PEG—
EV/EBITDA-2.26
EV/Revenue-115.58
P/S-74.37
P/B-0.53
EPS (TTM)-0.09 USD
EPS (Forward)-0.89 USD
52W Range
0.065818% of range0.1634
52W High0.1634 USD
52W Low0.0658 USD
Profitability
Gross Margin0.00%
Oper. Margin5098.01%
EBITDA Margin0.00%
Profit Margin-1203600.00%
ROE48.26%
ROA-145.78%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.06M USD
CapEx (TTM)4.39K USD
FCF Margin4945.27%
FCF Yield-66.50%
Net Debt12.25M USD
Net Debt/EBITDA-0.87
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.52
Current Ratio0.35
Quick Ratio0.29
Book Value/Sh-0.16 USD
Cash/Share0.0077 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.3345 USD
Upside (mean)+300.8%
Target Range0.2303 USD – 0.4387 USD
0.2303+300.8% to mean0.4387
# Analysts2
Ownership
Shares Out.245.28M
Float136.40M
Insiders6.75%
Institutions39.32%
Technical
SMA 500.0956 (-12.7%)
SMA 2000.0965 (-13.5%)
Beta0.70
S&P 52W Chg12.00%
Avg Vol (30d)758.87K
Avg Vol (10d)380.61K
Technical Indicators
RSI (14)47.7
MACD-0.0018
MACD Signal-0.0032
MACD Hist.+0.0013
BB Upper0.0874 USD
BB Middle0.0811 USD
BB Lower0.0748 USD
BB Width15.50%
ATR (14)0.0057 USD
Vol Ratio (20d)0.08x

About GenSight Biologics (EPA: SIGHT)

›

GenSight Biologics (EPA: SIGHT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.

The shares were at 0.0761 EUR on 19 November 2026, down 27.5% over 52 weeks. Its 52-week range is 0.0600 EUR to 0.1490 EUR: the price is 48.9% below the high and 26.8% above the low.

Its market capitalisation is 18.67M EUR.

GenSight Biologics reports return on equity of 48.3%.

Its debt exceeds its cash by 11.16M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.